Polymyxin B-Based Regimens for Patients Infected with Carbapenem-Resistant Gram-Negative Bacteria: Clinical and Microbiological Efficacy, Mortality, and Safety

References

• Brennan-Krohn T, Manetsch R, O’Doherty GA, Kirby JE. New strategies and structural considerations in development of therapeutics for carbapenem-resistant Enterobacteriaceae. Transl Res. 2020;220:14–32. doi:10.1016/j.trsl.2020.02.008
   PubMed Web of Science ®Google Scholar
• World Health Organization. Critically Important Antimicrobials for Human Medicine – 5th Rev. Geneva: World Health OrganizationLicence: CC BY‐NCSA3.0 IGO; 2017.
   Google Scholar
• Hu F, Guo Y, Yang Y, et al. Resistance reported from China antimicrobial surveillance network (CHINET) in 2018. Eur J Clin Microbiol Infect Dis. 2019;38(12):2275–2281. doi:10.1007/s10096-019-03673-1
   PubMed Web of Science ®Google Scholar
• Hu F, Guo Y, Zhu D. CHINET surveillance of bacterial resistance across tertiary hospitals in 2019. Chin J Infect Chemother. 2020;20(3):233–243.
   Google Scholar
• Bassetti M, Vena A, Sepulcri C, Giacobbe DR, Peghin M. Treatment of bloodstream infections due to Gram-negative bacteria with difficult-to-treat resistance. Antibiotics. 2020;9(9):632.
   Web of Science ®Google Scholar
• Paterson DL, Isler B, Stewart A. New treatment options for multiresistant gram negatives. Curr Opin Infect Dis. 2020;33(2):214–223. doi:10.1097/QCO.0000000000000627
   PubMed Web of Science ®Google Scholar
• Yu Z, Yu L, Zhu J. Patterns of polymyxin B use in eight major cities of China in its first year of use. J Glob Antimicrob Resist. 2020;20:342–343. doi:10.1016/j.jgar.2020.02.009
   Web of Science ®Google Scholar
• Xie J, Roberts JA, Lipman J, et al. Pharmacokinetic/pharmacodynamic adequacy of polymyxin B against extensively drug-resistant Gram-negative bacteria in critically ill, general ward and cystic fibrosis patient populations. Int J Antimicrob Agents. 2020;55(6):105943. doi:10.1016/j.ijantimicag.2020.105943
   Web of Science ®Google Scholar
• Tsuji BT, Pogue JM, Zavascki AP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10–39. doi:10.1002/phar.2209
   PubMed Web of Science ®Google Scholar
• Liang Q, Huang M, Xu Z. Early use of polymyxin B reduces the mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection. Braz J Infect Dis. 2019;23(1):60–65. doi:10.1016/j.bjid.2018.12.004
   PubMed Web of Science ®Google Scholar
• Cai Y, Leck H, Tan RW, et al. Clinical experience with high-dose polymyxin B against carbapenem-resistant Gram-negative bacterial infections-A cohort study. Antibiotics. 2020;9(8). doi:10.3390/antibiotics9080451
   Web of Science ®Google Scholar
• Zhao S, Yan L, Wang C, Peng M. [Clinical analysis of sepsis with extensively drug resistant Gram-negative bacteria in intensive care unit treated with polymyxin B-based combination therapy]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020;32(2):150–154. Chinese. doi:10.3760/cma.j.cn121430-20200108-00028
   Google Scholar
• Lu Q, Li GH, Qu Q, et al. Clinical efficacy of polymyxin B in patients infected with carbapenem-resistant organisms. Infect Drug Resist. 2021;14:1979–1988. doi:10.2147/IDR.S312708
   PubMed Web of Science ®Google Scholar
• Gibson GA, Bauer SR, Neuner EA, Bass SN, Lam SW. Influence of colistin dose on global cure in patients with bacteremia due to carbapenem-resistant Gram-negative bacilli. Antimicrob Agents Chemother. 2016;60(1):431–436. doi:10.1128/AAC.01414-15
   PubMed Web of Science ®Google Scholar
• Anania MC, Miranda C, Vizioli MG, et al. S100A11 overexpression contributes to the malignant phenotype of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2013;98(10):E1591–1600. doi:10.1210/jc.2013-1652
   Web of Science ®Google Scholar
• Satlin MJ, Lewis JS, Weinstein MP, et al. Clinical and laboratory standards institute and European committee on antimicrobial susceptibility testing position statements on polymyxin B and colistin clinical breakpoints. Clin Infect Dis. 2020;71(9):e523–e529. doi:10.1093/cid/ciaa121
   PubMed Web of Science ®Google Scholar
• Miglis C, Rhodes NJ, Avedissian SN, et al. Population pharmacokinetics of polymyxin B in acutely ill adult patients. Antimicrob Agents Chemother. 2018;62(3). doi:10.1128/AAC.01475-17
   Web of Science ®Google Scholar
• Doi Y. Treatment options for carbapenem-resistant Gram-negative bacterial infections. Clin Infect Dis. 2019;69(Suppl 7):S565–S575. doi:10.1093/cid/ciz830
   PubMed Web of Science ®Google Scholar
• Mattos KPH, Gouvea IR, Quintanilha JCF, Cursino MA, Vasconcelos P, Moriel P. Polymyxin B clinical outcomes: a prospective study of patients undergoing intravenous treatment. J Clin Pharm Ther. 2019;44(3):415–419. doi:10.1111/jcpt.12801
   Web of Science ®Google Scholar
• Chambers HF, Eliopoulos GM, Gilbert DNP, Saag MSE. Sanford Guide to Antimicrobial Therapy 2018. 48th edn. Sperryville, VA, USA: Antimicrobial Therapy; 2018.
   Google Scholar
• Sandri AM, Landersdorfer CB, Jacob J, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis. 2013;57(4):524–531. doi:10.1093/cid/cit334
   PubMed Web of Science ®Google Scholar
• Katip W, Uitrakul S, Oberdorfer P. A comparison of colistin versus colistin plus meropenem for the treatment of carbapenem-resistant acinetobacter baumannii in critically ill patients: a propensity score-matched analysis. Antibiotics. 2020;9(10). doi:10.3390/antibiotics9100647
   Web of Science ®Google Scholar
• Katip W, Oberdorfer P. Clinical efficacy and nephrotoxicity of colistin alone versus colistin plus vancomycin in critically ill patients infected with carbapenem-resistant acinetobacter baumannii: a propensity score-matched analysis. Pharmaceutics. 2021;13(2):162. doi:10.3390/pharmaceutics13020162
   PubMed Web of Science ®Google Scholar
• Klein DJ, Foster D, Walker PM, Bagshaw SM, Mekonnen H, Antonelli M. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the Euphrates trial. Intensive Care Med. 2018;44(12):2205–2212. doi:10.1007/s00134-018-5463-7
   Web of Science ®Google Scholar
• Lu Q, Zhu HH, Li GH, et al. A comparative study of the microbiological efficacy of polymyxin B on different carbapenem-resistant Gram-negative bacteria infections. Front Med. 2021;8:620885. doi:10.3389/fmed.2021.620885
   Web of Science ®Google Scholar
• Weiss SL, Fitzgerald JC, Balamuth F, et al. Delayed antimicrobial therapy increases mortality and organ dysfunction duration in pediatric sepsis. Crit Care Med. 2014;42(11):2409–2417. doi:10.1097/CCM.0000000000000509
   PubMed Web of Science ®Google Scholar
• Zhang X, Qi S, Duan X, et al. Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant Gram-negative bacterial infections: a real-world multicenter study. J Transl Med. 2021;19(1):431. doi:10.1186/s12967-021-03111-x
   PubMed Web of Science ®Google Scholar
• Elias LS, Konzen D, Krebs JM, Zavascki AP. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother. 2010;65(10):2231–2237. doi:10.1093/jac/dkq285
   PubMed Web of Science ®Google Scholar
• Azad MA, Akter J, Rogers KL, Nation RL, Velkov T, Li J. Major pathways of polymyxin-induced apoptosis in rat kidney proximal tubular cells. Antimicrob Agents Chemother. 2015;59(4):2136–2143. doi:10.1128/AAC.04869-14
   PubMed Web of Science ®Google Scholar
• Onufrak NJ, Rao GG, Forrest A, et al. Critical need for clarity in polymyxin B dosing. Antimicrob Agents Chemother. 2017;61(5). doi:10.1128/AAC.00208-17
   Web of Science ®Google Scholar
• Pogue JM, Ortwine JK, Kaye KS. Clinical considerations for optimal use of the polymyxins: a focus on agent selection and dosing. Clin Microbiol Infect. 2017;23(4):229–233. doi:10.1016/j.cmi.2017.02.023
   PubMed Web of Science ®Google Scholar
• Pogue JM, Ortwine JK, Kaye KS. Are there any ways around the exposure-limiting nephrotoxicity of the polymyxins? Int J Antimicrob Agents. 2016;48(6):622–626. doi:10.1016/j.ijantimicag.2016.11.001
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Dewan A. Comparison of nephrotoxicity of colistin with polymyxin B administered in currently recommended doses: a prospective study. Ann Clin Microbiol Antimicrob. 2018;17(1):15. doi:10.1186/s12941-018-0262-0
   PubMed Web of Science ®Google Scholar
• Katip W, Yoodee J, Uitrakul S, Oberdorfer P. Efficacy of loading dose colistin versus carbapenems for treatment of extended spectrum beta lactamase producing Enterobacteriaceae. Sci Rep. 2021;11(1):18. doi:10.1038/s41598-020-78098-4
   PubMed Web of Science ®Google Scholar
• Katip W, Uitrakul S, Oberdorfer P. Clinical efficacy and nephrotoxicity of the loading dose colistin for the treatment of carbapenem-resistant Acinetobacter baumannii in critically ill patients. Pharmaceutics. 2021;14(1):31. doi:10.3390/pharmaceutics14010031
   PubMed Web of Science ®Google Scholar
• Chang K, Wang H, Zhao J, et al. Risk factors for polymyxin B-associated acute kidney injury. Int J Infect Dis. 2022;117:37–44. doi:10.1016/j.ijid.2022.01.055
   Web of Science ®Google Scholar
• Nation RL, Rigatto MHP, Falci DR, Zavascki AP. Polymyxin acute kidney injury: dosing and other strategies to reduce toxicity. Antibiotics. 2019;8(1). doi:10.3390/antibiotics8010024
   Web of Science ®Google Scholar